Madrigal Pharmaceuticals (MDGL) Projected to Post Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($2.66) per share and revenue of $351.3880 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) EPS for the quarter, topping analysts’ consensus estimates of ($3.61) by $0.36. Madrigal Pharmaceuticals had a negative net margin of 27.32% and a negative return on equity of 50.15%. The business had revenue of $311.34 million for the quarter, compared to analyst estimates of $301.05 million. During the same quarter in the previous year, the firm posted ($3.32) earnings per share. The firm’s revenue for the quarter was up 126.8% on a year-over-year basis. On average, analysts expect Madrigal Pharmaceuticals to post $-7 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL opened at $538.80 on Wednesday. The stock has a market capitalization of $12.42 billion, a price-to-earnings ratio of -42.09 and a beta of -1.05. Madrigal Pharmaceuticals has a 12 month low of $286.44 and a 12 month high of $615.00. The firm has a fifty day simple moving average of $517.22 and a 200 day simple moving average of $499.48. The company has a current ratio of 3.50, a quick ratio of 3.16 and a debt-to-equity ratio of 0.63.

Insider Buying and Selling

In other news, insider David Soergel sold 1,042 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the transaction, the insider owned 10,033 shares of the company’s stock, valued at approximately $4,973,759.42. This represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $515.44, for a total value of $2,928,730.08. Following the transaction, the director owned 22,015 shares in the company, valued at approximately $11,347,411.60. This trade represents a 20.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 7,568 shares of company stock valued at $3,880,711. Corporate insiders own 17.60% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC bought a new stake in shares of Madrigal Pharmaceuticals in the second quarter valued at about $309,000. Qube Research & Technologies Ltd bought a new position in Madrigal Pharmaceuticals during the second quarter worth about $1,163,000. Sei Investments Co. raised its stake in Madrigal Pharmaceuticals by 73.6% in the 2nd quarter. Sei Investments Co. now owns 17,542 shares of the biopharmaceutical company’s stock worth $5,309,000 after purchasing an additional 7,438 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Madrigal Pharmaceuticals by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company’s stock worth $7,087,000 after purchasing an additional 471 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new stake in Madrigal Pharmaceuticals in the 2nd quarter valued at about $418,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Evercore set a $649.00 price target on shares of Madrigal Pharmaceuticals in a research report on Thursday, May 7th. Canaccord Genuity Group dropped their target price on Madrigal Pharmaceuticals from $587.00 to $578.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Piper Sandler restated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, June 24th. Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a research note on Monday. They set an “overweight” rating and a $685.00 price objective on the stock. Finally, Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $687.73.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.